By loading a chelation drug into a nano-sized homing device, researchers at Clemson University have reversed in an animal model the deadliest effects of chronic kidney disease, which kills more people in the United States each year than breast or prostate cancer.
When kidneys stop working properly, calcium builds up in artery tissue, leading to heart disease. Although nearly half a million Americans receive kidney dialysis, heart disease is the leading cause of death for people with chronic kidney disease.
“The findings are very exciting scientifically, but also for the thousands of patients who could potentially benefit from this technology one day,” said Naren Vyavahare, the Hunter Endowed Chair and professor of bioengineering at Clemson and the principal investigator of the research.
Chelation, a method of removing metals such as iron and lead from the body, has been used experimentally for some people with heart disease. The therapy is not approved by the Food and Drug Administration, but the National Institutes of Health has sponsored two large-scale, multi-center studies using ethylene diamine tetra-acetic acid, or EDTA, as chelation therapy for people with heart disease.
In clinical studies, EDTA is included in an infusion that circulates through the body; it’s systemic and non-specific. This method of chelation has shown good results in improving heart function, especially in diabetic patients, Vyavahare said. But EDTA infusion therapy is arduous (it requires 40 infusions over a period of a year), and it can cause side effects, including a depletion of calcium from the blood and from bone.
In 2014, Vyavahare’s team proved a targeted approach is effective. In animals without kidney disease, they loaded nanoparticles with EDTA and special antibodies that recognize and latch onto damaged elastin to deliver the therapy directly to arterial sites damaged by calcification.
Now, in a paper published Feb. 22, 2019, in Scientific Reports, a Nature publication, Vyavahare’s team describes how they developed an animal model that mimics a human’s chronic kidney disease. Animals were treated either with EDTA infusions, like in the NIH human trials, or with EDTA enclosed in a nanoparticle coupled with an antibody that seeks out damaged elastin. In animals that received the targeted therapy, calcium buildup was destroyed, without causing side effects, better than with EDTA infusions alone. Moreover, the calcification did not come back up to four weeks after the last injection, even though other signs of chronic kidney disease were present.
“Dr. Vyavahare’s work is extremely important for those of us who believe that calcium is not just a passive indicator of coronary disease, but also an active participant,” said Gervasio Lamas, chairman of medicine and chief of cardiology at Mount Sinai Medical Center in Miami Beach, Florida. Lamas, principal investigator of the NIH-funded Trial to Assess Chelation Therapy 2, was not involved in the Clemson study.
“The potential with a targeted drug is enormous, and the methodology for targeting that Dr. Vyavahare has developed is unique,” Lamas said.
Vyavahare and his co-authors wrote that in a previous study they showed that polyphenols, when delivered with nanoparticles, “regenerate degraded aortic elastin. Thus, there is an exciting opportunity of dual nanoparticle therapy to first remove calcium deposits using EDTA and then restore medial elastin layers with (polyphenols).”
Vyavahare has been studying elastin degradation and damages caused by calcification for nearly 20 years. He’s director of the NIH-funded South Carolina Center of Biomaterials for Tissue Regeneration.
The nanoparticle delivery technology has been licensed by Elastrin Therapeutics, a startup company Vyavahare helped found. He serves as chief science officer of the company.
“With recent funding we received from NIH to carry out more studies on understanding how reversal of calcification works, and Elastrin Therapeutics Inc. licensing this technology from Clemson University, we believe we would be able to translate this approach for use in clinical trials within the next few years,” Vyavahare said.
The Latest on: Chronic kidney disease
via Google News
The Latest on: Chronic kidney disease
- Treatment for coronary heart disease is just as good as stents or bypasson November 18, 2019 at 3:48 pm
The results of the ISCHEMIA trial, reported at the American Heart Association’s scientific sessions (2019) show that the conservative management of patients with cardiovascular disease and chronic ...
- High-protein diets may affect kidney healthon November 18, 2019 at 9:42 am
A high-protein diet induces glomerular hyperfiltration, which, according to our current state of knowledge, may boost a pre-existing low-grade chronic kidney disease, which, by the way, is often ...
- Penn-Harris-Madison rallies around 11-year-old student fighting kidney diseaseon November 18, 2019 at 3:20 am
It’s a dialysis machine with soft tubes, needles, fluid bags and a dialyzer (also called an artificial kidney). Alex has Stage 5 Chronic Kidney Disease. Over the past year-and-a-half, Amber Deranek, ...
- Chronic Kidney Disease (CKD) Drugs Market 2019 Global Analysis & Forecast to 2023 Market Research Reporton November 18, 2019 at 2:53 am
With an increase in the incidence of chronic kidney conditions, report analysts believe that the global market for chronic kidney disease drugs will witness good growth over the forecast period.
- Genetic Characteristics of Korean Patients with Autosomal Dominant Polycystic Kidney Disease by Targeted Exome Sequencingon November 18, 2019 at 2:23 am
Autosomal dominant polycystic kidney disease (ADPKD) is a potentially lethal monogenic disorder characterized ... Baseline demographic profiles were collected including age, gender, height, ...
- Chronic Kidney Disease Drugs Market Opportunities, Size, Share, Emerging Trends, Technological Innovation And Forecasts To 2025on November 17, 2019 at 10:42 pm
Nov 18, 2019 (AmericaNewsHour) -- Global Chronic Kidney Disease Drugs Market - Drivers, Restraints, Opportunities, Trends, and Forecast up to 2025 [85 pages report] This market research report ...
- New Boston teen escorted home after receiving new kidneyon November 17, 2019 at 2:26 am
Her uncle donated a kidney to her in 2008, but her body rejected it in 2017.She was diagnosed with end-stage renal disease, a chronic kidney condition. This caused her to be on dialysis for about two ...
- ISCHEMIA-CKD Trial: Advanced Chronic Kidney Disease Patients Treated with Invasive Heart Procedures Show No Reduction in Rate of Cardiac Eventson November 16, 2019 at 10:15 am
BROOKLYN, N.Y., Nov. 16, 2019 /PRNewswire/ -- Heart disease is the leading cause of death for the roughly 500 million people worldwide with chronic kidney disease (CKD). Yet such patients have been ...
- Metabolic acidosis is associated with pulse wave velocity in chronic kidney disease: Results from the KNOW-CKD Studyon November 13, 2019 at 6:39 pm
The KoreaN Cohort Study for Outcome in Patients With Chronic Kidney Disease (KNOW-CKD) was a Korean multicenter prospective cohort study that enrolled subjects with CKD from stage 1 to 5 (predialysis) ...
- A New Study Suggests Intervention for Kidney Disease Can Reduce Hospitalizations and Costson November 12, 2019 at 4:06 pm
found that detecting chronic kidney disease (CKD) with two simple tests and treating it based on severity can improve health outcomes for patients with diabetes and hypertension and lower the cost of ...
via Bing News